Bristol Myers Squibb Maintains 2026 Eliquis Revenue Growth Expectation
Bristol Myers Squibb continues to expect worldwide Eliquis revenue to increase in 2026 compared with 2025.
Related stories
ATI Reports Third-Quarter 2026 Sales of $1.42 Billion, EPS of $1.37
ATI said sales rose 26.5% year over year to $1.42 billion, net income increased 72.5% to $189.8 million, and diluted EPS rose to $1.37 from $0.78. The company cited aerospace and d
M impact | EARNINGS | Oct 29, 2026, 06:21 PM UTC
Federal Signal Reports Results for Quarter Ended September 30
M impact | EARNINGS | Oct 29, 2026, 06:20 PM UTC
Ambev earnings above expectations at 0.28 BRL
Ambev (ABEV3) released earnings per share at 0.28 BRL, compared to market expectations of 0.25 BRL.
H impact | EARNINGS | Oct 29, 2026, 06:12 PM UTC
Prysmian earnings above expectations at 1.65 EUR
Prysmian (PRY) released earnings per share at 1.65 EUR, compared to market expectations of 1.48 EUR.
H impact | EARNINGS | Oct 29, 2026, 06:12 PM UTC
Exchange Bank Reports Q3 Net Income of $8.9M, NII Up 8.4%
Unaudited Q3 2026 net income was $8.9 million, compared with $8.6 million a year earlier. Net interest income rose 8.4% to $25.2 million as interest expense declined.
M impact | EARNINGS | Oct 29, 2026, 06:01 PM UTC
Exchange Bank Reports Third-Quarter 2026 Net Income of $8.9 Million
Exchange Bank reported unaudited net income after taxes of $8.9 million for the quarter ended September 30, 2026, and $23.7 million for the nine months ended September 30.
M impact | EARNINGS | Oct 29, 2026, 06:00 PM UTC